Radiopharm Theranostics To Meet FDA On Phase 3 Design For RAD101; Phase 2b Shows 93% MRI Concordance
· rttnews.com
Radiopharm Theranostics Ltd. (RADX), a clinical-stage biopharmaceutical company developing radiopharmaceuticals for oncology, announced that it has scheduled an End-of-Phase 2 meeting with the U.
Radiopharm Theranostics Ltd. (RADX), a clinical-stage biopharmaceutical company developing radiopharmaceuticals for oncology, announced that it has scheduled an...